Acadia Pharmaceuticals Appoints Vertex Finance Leader Jonathan Poole To Board Of Directors, Strengthening Financial And Audit Oversight

Acadia Pharmaceuticals Inc. has appointed Jonathan M. Poole to its Board of Directors, effective March 3, 2026. He will also serve on the company’s Audit Committee, bringing extensive financial leadership experience within the biopharmaceutical sector, particularly in supporting global growth and innovation across diverse therapeutic areas.

“I am honored to join Acadia’s Board of Directors,” said Mr. Poole. “I look forward to working with the Board and management team to support the Company’s mission of developing and delivering innovative therapies for patients with significant unmet needs.”

Since March 2020, Poole has served as Senior Vice President, Finance at Vertex Pharmaceuticals, Inc., overseeing global finance operations during a period marked by significant R&D expansion, commercial growth, and multiple acquisitions. His responsibilities have included guiding financial strategy through portfolio diversification and integration activities.

“Jonathan brings extensive biotechnology corporate leadership experience and a proven track record of supporting significant business growth across complex, global organisations,” said Stephen R. Biggar, M.D., Ph.D., Chairman of Acadia’s Board of Directors. “His appointment further strengthens the Board’s financial and operational expertise at a pivotal time as Acadia continues to execute its growth strategy, advance its commercial portfolio and pipeline, and deliver sustained, long‑term value for shareholders.”

Earlier in his career, Poole served as Chief Financial Officer at Evelo Biosciences, Inc. from 2018 to 2020 and at Genocea Biosciences, Inc. from 2014 to 2018, where he supported the development of therapies targeting inflammation, cancer, and infectious diseases. He also served as a board director and Audit Committee Chair at Codiak Biosciences, Inc. between 2018 and 2020. Poole holds a Bachelor of Science in Biological Sciences from Durham University in the United Kingdom and an MBA from London Business School.